Traditionally, reflux esophagitis was assumed to develop as an acid burn in which esophageal squamous epithelial cells succumbed to the caustic chemical effects of refluxed gastric acid [1] . The acid-induced death of esophageal surface cells was thought to incite an acute, granulocytic inflammatory response that started in the epithelium and later progressed into the lamina propria and, with ulceration, into the submucosa. The loss of esophageal surface cells also was assumed to stimulate hyperplasia of progenitor cells in the basal layer of the squamous epithelium, which is a characteristic histologic feature of gastroesophageal reflux disease (GERD) [2, 3] .
Cytokine sizzle
In 2009, the acid burn concept of reflux esophagitis was challenged in a report describing the histologic progression of GERD in rats that had reflux induced by creating an esophago-duodenostomy [4] . Reflux esophagitis in these animals began, not with the death of surface cells and epithelial infiltration by granulocytes, but rather with T lymphocytes infiltrating the esophageal submucosa first, and later progressing into the lamina propria and epithelium. Surface cell erosions did not appear until weeks after esophago-duodenostomy, and basal cell hyperplasia developed well before the loss of surface cells. The report also described in vitro studies showing that acid and bile salts caused human esophageal epithelial cells in culture to secrete pro-inflammatory and proproliferative cytokines such as interleukin (IL)-8. These findings suggested an alternative hypothesis for reflux esophagitis pathogenesis in which refluxed gastric juice did not kill esophageal epithelial cells directly, but rather stimulated them to secrete cytokines that induce epithelial proliferative changes and attract the T lymphocytes and other inflammatory cells that ultimately damage the mucosa. Thus, reflux esophagitis appears to develop as a cytokine sizzle.
A recent clinical study explored this hypothesis that reflux esophagitis develops as a cytokine-mediated injury rather than as an acid burn [5 ] . In 12 patients with reflux esophagitis healed by proton pump inhibitors (PPIs), the investigators induced acute esophagitis by interrupting PPI therapy. Endoscopic examinations performed at 1 and 2 weeks after stopping PPIs showed that all patients had redeveloped reflux esophagitis within two weeks, and esophageal biopsies confirmed that, as in the rat model, acute reflux esophagitis in humans begins with T lymphocyte-predominant inflammation and with basal cell hyperplasia developing before the loss of surface cells. These findings support a cytokine-mediated pathogenesis for reflux esophagitis.
Hypoxia-inducible factor-2a: a key mediator of the cytokine sizzle HIF-2a stabilization and signaling
The same group subsequently explored a role for hypoxia inducible factors (HIFs) in mediating the GERDinduced release of pro-inflammatory cytokines by the esophagus. HIFs are transcription factors that enable cells to respond to hypoxic stress, and HIFs are known to mediate some inflammatory processes [6] [7] [8] [9] . HIF proteins are heterodimers comprising a HIF-1b subunit that is expressed constitutively and a HIF-a subunit that can be regulated by oxygen [9] . Under normal oxygen conditions, prolyl hydroxylases (PHDs) in the cytoplasm catalyze the hydroxylation of proline residues in the oxygen-dependent degradation domain of HIF-a, and this hydroxylation initiates the rapid degradation of HIF-a by proteasomes. Hypoxia decreases PHD activity, thereby preventing proteasomal degradation of the HIFa subunitÁ Thus, hypoxia stabilizes HIFs and enables them to accumulate in the cytoplasm and translocate to the nucleus to induce transcription of their target genes, which can include pro-inflammatory cytokines [10] . Like hypoxia, reactive oxygen species (ROS) also can decrease PHD activity and stabilize HIF proteins, and esophageal squamous cells exposed to acid and bile salts in vitro have been shown to produce ROS [11] . On the basis of these observations, the investigators hypothesized that refluxed acid and bile salts cause esophageal squamous epithelial cells to produce ROS that inactivate PHDs, enabling HIFs to accumulate and to stimulate the production of pro-inflammatory molecules [12 ] .
HIF-2a in human reflux esophagitis
Using esophageal biopsy specimens taken from GERD patients in the aforementioned clinical study at 1 and 2 weeks after stopping PPIs, the investigators noted that the development of acute reflux esophagitis was associated with a significant increase in epithelial immunostaining for HIF-2a and phosphorylated NF-kB subunit p65 (phospho-p65), and with increased mRNA expression of a number of pro-inflammatory mediators including IL-8, IL-1b, tumor necrosis factor (TNF)-a, cyclooxygenase (COX)-2, and intercellular adhesion molecule (ICAM)-1 [12 ] . Using the statistical technique of computing eta 2 values for non-linear correlations, large associations were found among levels of HIF-2a and phospho-p65 and mRNA expression of the pro-inflammatory mediators. These findings suggest that the development of reflux esophagitis is associated with increases in HIF-2a that appear to contribute to increased NF-kB/p65 activity, which in turn appears to contribute to increased expression of pro-inflammatory mediators in esophageal squamous epithelium.
Reflux-induced HIF-2a stabilization and signaling in esophageal squamous cells in vitro
The investigators also performed in vitro studies in human esophageal squamous cell lines showing that acidic bile salts decrease PHD function by generating intracellular ROS through the squamous cell's NADPH oxidase system ( Figure 1 ) [12 ] . This ROS-induced decrease in PHD function caused a sustained increase in squamous cell levels of HIF-2a, which mediated an NF-kB/p65-dependent inflammatory response with an increase in expression of pro-inflammatory molecule mRNAs. In addition, conditioned media from esophageal cells that were treated with acidic bile salts were found to increase T cell migration rates in a transwell system. Finally, HIF-2a knockdown by shRNA and HIF-2a inhibition using a selective small molecule antagonist (S,R)-4 ( Figure 2 ) [13] blocked the increases in proinflammatory molecule expression and T cell migration induced by acidic bile salts [12 ] . (Note that (S,R)-4 was named (S,R)-37 Peak 2 in Reference [12 ] .) These observations support the hypothesis that reflux esophagitis develops through a cytokine-mediated process in which HIF-2a plays a central role ( Figure 1 ). Since HIF-2a appears to play such a central role in the esophageal epithelial inflammatory response to gastroesophageal reflux in vitro, further studies using HIF-2a inhibitors in animal models of reflux esophagitis are clearly warranted.
Isoform-selective HIF-2a inhibitors
Small molecule inhibition of the HIF family of transcription factors is recognized as a potentially valuable therapeutic approach to treat HIF-dependent diseases. Although several high throughput screen-derived synthetic small molecules and natural products have been reported to inhibit the HIF pathway [14] [15] [16] [17] , most of these directly interact with targets other than the HIF proteins themselves, limiting their utility in testing HIFcentric therapeutic hypotheses.
In one study, Bruick, Gardner, MacMillan, and Tambar exploited an unusually large 290 Å 3 cavity buried within the Per-ARNT-Sim (PAS)-B domain of the HIF-2a isoform to demonstrate allosteric inhibition via direct small molecule binding (Figure 2a ) [18, 19] . An extensive high throughput screen of more than 200 000 small molecules was performed to detect direct small molecule interaction with HIF-2a PAS-B [20, 21] . 'Hits' within the screening process were determined based on a compound's ability to inhibit HIF-2a-HIF-b heterodimerization in a homogenous, bead-based luminescence proximity assay (AlphaScreen). The most effective small molecule disrupters of HIF-2a-HIF-b heterodimerization possessed the general structure of compound 1, which served as a starting point for structure-activity-relationship (SAR) studies. Diversification of 1 to a variety of HIF-2a antagonists focused on three major regions: (1) modification of the left-hand A-ring portion characterized by a nitrobearing oxadiazole, (2) variation of the central heteroatom-containing linker, and (3) diversification of the right hand aromatic B-ring region. Ultimately, analogue 2 exhibited the strongest inhibitory activity in this structural class.
To better understand the nature of the interaction of HIF-2a and inhibitor 2, NMR-based structural analysis was paired with X-ray crystallographic studies [20] . A cocrystal structure of inhibitor 2 shows the compound bound within the HIF-2a PAS-B internal cavity, favoring a weak electrostatic interaction between the nitro functionality of the A-ring and the H248 imidazole side chain. The specificity in positioning required to accommodate this interaction situates the B-ring of the molecule adjacent to the b-sheet, inducing a series of notable conformational changes throughout the domain as observed by 15 N/ 1 H HSQC NMR studies of a 15 N-enriched HIF-2a PAS-B-2 complex. While these conformational changes perturb interactions mediated through the b-sheet observed between isolated PAS domains [20] , additional effects on residues residing on the opposing face of the domain may interfere with key dimer contacts observed in structures of the complete HIF heterdimerization units [22, 23 ].
Isoform selective HIF-2a inhibitors-the next generation
Subsequent to this original study, Bruick, Gardner, MacMillan, and Tambar identified a more potent class of inhibitors of HIF-2a-HIF-b heterodimerization, which are based on a tetrazolo-tetrahydropyrimidine ring system (3, Figure 2b ) [13] . This general pharmacophore is preferred over compound 2 for several reasons. While the nitro functionality in compound 2 proved to be necessary for activity, it also posed pharmacokinetic disadvantages that are averted in this second scaffold. Additionally, tetrazole moieties increase compound solubility and have been widely studied as pharmacophores for carboxylic acids [24, 25] . Finally, these compounds are unique in that Proposed mechanism for the pathogenesis of reflux esophagitis. Esophageal squamous epithelial cells exposed to refluxed acid and bile salts generate intracellular ROS via NAPDH oxidase. ROS decrease the activity of PHD, the enzyme that initiates proteasomal degradation of HIF-2a. The decreased PHD activity stabilizes HIF-2a and enables it to accumulate in the cytoplasm. The stabilized HIF-2a then can translocate to the nucleus to induce transcription of pro-inflammatory cytokine genes that have hypoxia responsive elements (HREs) in their promoter regions. The stabilized HIF-2a in the cytoplasm also can increase levels of phospho-p65, enabling it to translocate to the nucleus and bind the NF-kB gene promoter, which further stimulates production of the pro-inflammatory cytokines that mediate the development of reflux esophagitis. ROS = reactive oxygen species, PHD = prolyl hydroxylase, HIF = hypoxia inducible factor, HRE = hypoxia responsive element, NF-kB = nuclear factor kB.
they are chiral molecules and thus may prove to exhibit interesting selectivity.
After extensive structure-activity-relationship studies, tetrazolo-tetrahydropyrimidine (S,R)-4 was identified as high affinity binding, effective, isoform-selective inhibitor of HIF-2a in cells. Further examination revealed stereo-preferential binding of this compound, where 
Comparison of ternary complex (S,R)-4-HIF-2a PAS-B to
2-HIF-2a PAS-B revealed that both small molecules bind within the same buried cavity of the PAS-B domain and share many structural similarities as well as some dissimilarities that may account for the enhanced binding witnessed with inhibitor (S,R)-4 ( Figure 2c ). The more pronounced binding interactions observed with (S,R)-4-HIF-a PAS-B lead to a series of conformational changes within the binding domain, allowing for an expanded internal cavity 40-65% larger in volume than that seen with inhibitor 2 and increasing the disruption of important intermolecular contacts with the HIF-b PAS-B domain.
These improved analogs feature sufficient potency and pharmacologic properties to demonstrate efficacy in cultured cells [13, 20] . Both compounds 2 and (S,R)-4 antagonize HIF-2a-HIF-b heterodimer formation. The diminished HIF-2 DNA-binding activity results in decreased expression of HIF-2a target genes. These effects are not observed with the inactive (R,S)-4 enantiomer. Moreover, these compounds are selective for HIF-2a; no inhibition of HIF-1a target gene expression was observed. Despite the >70% identity between the HIF-1a and HIF-2a PAS-B domains, several bulkier residues face the internal HIF-1a cavity to preclude inhibitor binding. Effectively, nature has provided an endogenous internal control to assess the on-target effects of these compounds. These 'tool' inhibitors are suitable for proof-of-concept studies in cultured cells.
Clinical application of HIF-2a small molecule inhibitors
Excitingly, insights gleaned from these lead compounds served as the launching point for a comprehensive medicinal chemistry effort by Peloton Therapeutics, Inc. to improve inhibitor potency, selectivity, pharmacokinetic, and toxicity profiles. These efforts have led to the successful development of well-tolerated HIF-2a inhibitors capable of selectively antagonizing HIF-2a in vivo in preclinical animal models [23 ,26,27] .
For example, PT2385, binds tightly to the HIF-2a PAS-B domain (K d $ 50 nM) with no measurable association with HIF-1a [23 ] . In mice, a single oral dose of 10 mg/kg PT2385 produces high plasma concentrations (>1 mM; 95%F; T 1/2 4 h) [23 ] . To test whether this selective antagonist would be efficacious in treating HIF-2-driven cancers, PT2385 was administered to clear cell Renal Cell Carcinoma xenograft tumor models derived from cell lines and patient tumors. The expression of HIF-2-dependent target genes was markedly decreased in tumors excised from mice treated with 10 mg/kg PT2385 b.i.d. for three days while no changes in HIF-1-selective target genes were observed. Prolonged treatment with PT2385 for 20-30 days, at doses as low as 3 mg/ kg b.i.d. in some cases, resulted in rapid tumor regression or stasis in several models and was accompanied by decreases cellular proliferation and microvessel density [23 ] . Similar results were observed by other investigators using the related HIF-2 antagonist, PT2399. In these studies, PT2399's effects on gene expression and tumor growth were confirmed to be 'on-target' as drug resistance was conferred upon introduction of mutations that occlude the HIF-2a PAS-B cavity [26, 27] .
As expected, these inhibitors also antagonized the expression of the HIF-2-selective target gene encoding erythropoietin (EPO) in the kidneys of mice and rats, resulting in mild reductions in haemoglobin and reticulocyte levels [23 ,26,27] . Nevertheless, these agents were very welltolerated in all studies, with no indication of adverse events such as weight loss or behavioral changes [23 ,26,27] . Importantly, PT2385 dosed as high as 60 mg/kg q.d. in rats did not induce changes in blood pressure, heart rate, or pulse pressure even though circulating tumor-derived VEGF-A levels were decreased [23 ] . Though VEGF expression in these tumors appears to be primarily driven by HIF-2, the expression of hostderived VEGF can be governed by either HIF-1 or HIF-2 and was not significantly altered by the HIF-2 antagonist [23 ] . In contrast, antiangiogenic agents such as Tyrosine Kinase Inhibitors (TKIs), which likewise target VEGF/ VEGFR2 signaling, exert effects on both the host and tumors that can limit use due to cardiovascular concerns, including hypertension [23 ,28,29] .
These preclinical safety and efficacy results support the feasibility of targeting the HIF-2a transcription factor in therapeutic settings. Clinical trials with PT2385 or related inhibitors for the treatment of HIF-2a driven kidney cancers are ongoing (ClinicalTrials.gov Identifiers: NCT02553356, NCT02293980, NCT03108066, and NCT02974738).
Conclusion: implications for HIF-2a inhibitors in reflux esophagitis
Instead of the traditional notion that refluxed gastric acid causes a chemical burn in the esophagus, the studies discussed above suggest that refluxed acid and bile salts cause esophageal epithelial cells to produce ROS that decrease PHD activity, thereby stabilizing HIF-2a and enabling it to accumulate in the cytoplasm and translocate to the nucleus. In the nucleus, HIF-2a stimulates the production of pro-inflammatory cytokines. HIF-2a in the cytoplasm also mediates the activity of phospho-p65, enabling it to translocate to the nucleus and bind the NF-kB gene promoter, which further stimulates production of the pro-inflammatory cytokines that mediate the development of reflux esophagitis. Medicinal chemistry efforts have led to the development of well-tolerated, exquisitely selective HIF-2a inhibitors that can be used in vivo in preclinical and in clinical studies. Commercial availability of these HIF-2a inhibitors has put preclinical studies in animal models of GERD within reach. Since HIF-2a appears to play such a central role in the esophageal epithelium's inflammatory response to gastroesophageal reflux, a HIF-2a-directed therapy might be on the horizon as a novel approach to the prevention and treatment of reflux esophagitis.
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